{"name":"Traws Pharma, Inc.","slug":"traws-pharma-inc","ticker":"","exchange":"","domain":"trawspharma.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"ON 01910.Na and oxaliplatin","genericName":"ON 01910.Na and oxaliplatin","slug":"on-01910-na-and-oxaliplatin","indication":"Other","status":"phase_1"},{"name":"TRX-100","genericName":"TRX-100","slug":"trx-100","indication":"Other","status":"phase_2"},{"name":"irinotecan and ON 01910.Na","genericName":"irinotecan and ON 01910.Na","slug":"irinotecan-and-on-01910-na","indication":"Other","status":"phase_1"},{"name":"oxaliplatin and ON 01910.Na","genericName":"oxaliplatin and ON 01910.Na","slug":"oxaliplatin-and-on-01910-na","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ON 01910.Na","genericName":"ON 01910.Na","slug":"on-01910-na","indication":"Relapsed or refractory acute myeloid leukemia","status":"phase_3"}]}],"pipeline":[{"name":"ON 01910.Na","genericName":"ON 01910.Na","slug":"on-01910-na","phase":"phase_3","mechanism":"ON 01910.Na is a small molecule that targets the MDM2 protein.","indications":["Relapsed or refractory acute myeloid leukemia"],"catalyst":""},{"name":"ON 01910.Na and oxaliplatin","genericName":"ON 01910.Na and oxaliplatin","slug":"on-01910-na-and-oxaliplatin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TRX-100","genericName":"TRX-100","slug":"trx-100","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"irinotecan and ON 01910.Na","genericName":"irinotecan and ON 01910.Na","slug":"irinotecan-and-on-01910-na","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"oxaliplatin and ON 01910.Na","genericName":"oxaliplatin and ON 01910.Na","slug":"oxaliplatin-and-on-01910-na","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPYlJHM1NiSDEwMDQzeGtSSGpSX205aFZFeXFxa2RZRHVNSTFScXVLb1J0eXExaHZXRnJvOEhmejBXMjVldmdzTHZuNUljcHNiZUtDNnBKSEVFTU53R3cyOHdMcHExdmVra0hhM2hrRlIwVzlGakJRRHEwUDF4djdaemtQUDhNbEVNb1RENWk2RFlhNEk2Q0NEUzZZcDVSMFRaWGJGMDRwVnlLNXl2NzJ4OFVKN3JYQlU5TlZObWNFQ3lDcmFwRFE?oc=5","date":"2026-04-08","type":"pipeline","source":"Stock Titan","summary":"Traws Pharma (TRAW) CFO Parker Nolan listed as insider in Form 3 - Stock Titan","headline":"Traws Pharma (TRAW) CFO Parker Nolan listed as insider in Form 3","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTEFVX3lxTE5uMGU4TE92Q29oVjVtTEdIN1Y4UjZKUVlqbGV4X2NMWnZUb2Fmc05WMEV2Sm02ZHZBZm1xcGEza2RFWndMTUUxX1FlQnE?oc=5","date":"2026-04-02","type":"pipeline","source":"StocksToTrade","summary":"Traws Pharma Inc. (TRAW) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade","headline":"Traws Pharma Inc. (TRAW) Stock Price | Live Quotes & Charts | NASDAQ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPVHdqTmRKRzYtdFluWW9uVFBJOGVtRmpsUXBnVndhMFpxLV91M0FUSHBnamM3OVp3ZmZZQUprajhCUzg5Y3NjZ1lEeXJ2ZU1la1RLT2NyQXdpZmZ5TmREQlc0VVRlajNTeUY3NEFTeGVIM2J2MVlRaTBCcXFMckgyM0hVZWM4RU4ydlJoYnhscWxZT21ZTFhKUVFQN3VMYnM?oc=5","date":"2026-04-01","type":"pipeline","source":"TipRanks","summary":"Traws Pharma Delays 10-K Amid Financing Review - TipRanks","headline":"Traws Pharma Delays 10-K Amid Financing Review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxORWVROEFkd3BPcVMtZlBqVWFHcEQwbjlwT09KUWppenRNdk1iZU1OSU1fS0ViaDlPeWIyOWxQVko5ODFxd1c2WjVqWm1DRTlmbURKSmtlTGFGaWp0Yk5nZFk4SVNhUkhBeEVGWjNXYVlNTzZiUEhwNXBkN3Vlc3VGSmpsUDNtMmlsaU51M0lqSW1yQTlseFA3RkxxX044UQ?oc=5","date":"2026-03-31","type":"pipeline","source":"Stock Titan","summary":"Traws Pharma (TRAW) delays 2025 Form 10-K, cites financing and going-concern review - Stock Titan","headline":"Traws Pharma (TRAW) delays 2025 Form 10-K, cites financing and going-concern review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPRkt3VjYyclhUdG5XMFZfOW8xUS1PYk41QzJYZEp0UmhXeUktcGd6emt0V3ZEVmNsTVlFRkpWQnBjNm50ZkoyNXpDeDdadDFiUmp3Yl9NWEdQOG1GeDJqam5NQTFGQ1E0VmtiUHYtcmhJNnlCUjhSZ25LR0FvQ2FOcTBxWkM1aF85eWdJbVNqX0lweURNeTZfRHFCRmZpVzFZY3VOV1VvR1dFNGlCRWFScEIxaWdSd1lwODlsSlZFZWJMZnpQem1OYlZ5ZHAxVldJRTFXNDVDdWNpMWM?oc=5","date":"2026-03-27","type":"earnings","source":"TradingView","summary":"Traws Pharma Inc expected to post a loss of $1.22 a share - Earnings Preview - TradingView","headline":"Traws Pharma Inc expected to post a loss of $1.22 a share - Earnings Preview","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQcmNISHRPYTRDSXFmaE42ZkI3N1FMNFo4b2hZQ0ZJUXlXNTNHQllWQnR3UGhqSy1VSlg1M3pXRUZVZGwzMFdzU256dk9GUzYwdnJBNXJxb0dqa0p1LUNXdWpad01GVFFXUWhFVjN3RmdWbzFiNWdHS0Nhcm8wOWZHaFpFUENpbEw5RUMzNWZ6RGxMT3FYQkJiTXlKNnJoMVFVWlFpYk1EOWJzNmNUMXhV?oc=5","date":"2026-03-10","type":"pipeline","source":"Stock Titan","summary":"Traws Pharma (TRAW) awards 33,435 stock options to director Jack Stover - Stock Titan","headline":"Traws Pharma (TRAW) awards 33,435 stock options to director Jack Stover","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2AFBVV95cUxNeGhDaHlkNjY0ckZQbGd3ZktGWTIzSGxFUVRTanI4YjFiT016dFRGSHVQSUFua2R3UlJUXzhmMmZuTU1aTmZPdmNMS0NONFdZdzJMcHNkdTNIWjRIQWxSamRvMnJYZHBoSDlLY3ZldW1GRDdSRDM1ZUJXejdVamJMZXhleHlVbVF2aDE3cUFqdXVxYzFqMnZxcnBjVVJmeU1RR1BXeUtsb3hWZVhQTnFtamh0X1BIVGlibk1wVEFMc0NNckZYMDFMbnpiazhTVi1tNkhyTEI2bWE?oc=5","date":"2026-02-19","type":"regulatory","source":"Investing.com","summary":"Traws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical hold - Investing.com","headline":"Traws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical hold","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOS2lKMm85TnR1eDVKeUZ5Tl9UTGJIMWtRd3hmOWhaUVJUdjR3WGcwVlVhaTJncDlKYTE1Y3Y2ekdENFU4LWdrUnJHRUt3RGpTQnYxTjlVYS1Ib1o3UVYxdFZBZE9rZVdKS1ZfdFBGVXB4T3FZYVd2R1UwYjZYWnEzRUltalRQWXJJVjVpMXd6XzY3UmduLWc?oc=5","date":"2026-01-26","type":"trial","source":"Yahoo Finance","summary":"Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Tr","headline":"Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQRnBDMmFKMkY5YWUxbGJjd0ZGanU2ZGE0SXBGM0tVZnZhV3NtRTlDLTFhcFpZbXJLVjZvSl95TjZTdDZkc3E3WU1hUzdYcGFQd0JKTTdWd3hOZjVtM01Kb1I0LWExeFFaeHFIa0w2bFhnTFF3dGlMQkl6VktPdmJaZlJ4c3RzbkdfWV9sZXZzQ1RmQUhsd3l0dVZ2ZzYwQ2d1bWxtbUJrRzVTVXJFUER1NjZieTNTMlQwSzdhY04xY0ZoQU54ckE?oc=5","date":"2026-01-26","type":"trial","source":"Investing.com","summary":"Traws Pharma stock soars after completing COVID-19 treatment study - Investing.com","headline":"Traws Pharma stock soars after completing COVID-19 treatment study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxORGllOFBJdHAxUC1jUGhJaS05MGdOVHVYMG5ybDNQUzgwZTROVFRZc2JLVFctYnctX0VmRnhEUzIxLV9xOVBuOEJJd19NUE5aQnc1SnNEZFRWRTVEX0lTQ0lNTjZzTVFwRHJ5MW15UlF0Y1JJOWMxY2t2dXZhUzRFTjZqY0xjdFE4THRZ?oc=5","date":"2025-12-17","type":"trial","source":"Yahoo Finance","summary":"Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients - Yahoo Finance","headline":"Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Inelig","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxORS1zc2czelE3Z3pwV1BHbWpObVY0ZS12bXRySUxROU56YVpDODNsdUM0bGpCcElQYWRWdnhoejlKRFd6WHAtVVFVMFpOa1VHNEFDWE8tUnkzY3JWWWxoTzd1dG4tY0ZIQXc0MTE5TzdoNTM4Y3luODEyd2RRZGhqcDJ4TGdHNUdKZ1lybjdwR01VTjB1QkU3czVR?oc=5","date":"2025-11-13","type":"pipeline","source":"TradingView","summary":"Traws Pharma, Inc. SEC 10-Q Report - TradingView","headline":"Traws Pharma, Inc. SEC 10-Q Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOZFdhSDZ5SnpCWUFCSHN2QWtFcUdVd0F0MUxYMHJLZzE4bWRrUC1PQmRfcXV6V1JzbmhvcHpYOHo2aDdtSGNHc1h5STRHNDBUUGRibzdldGtCSXNILV9DSFBXaktoMWRvRU1zMHF2aWdhVExhYmpYQklEZUp4bFFqU3h4WTRaSGRs?oc=5","date":"2025-08-14","type":"earnings","source":"Yahoo Finance","summary":"Traws Pharma Reports Second Quarter 2025 Results and Business Highlights - Yahoo Finance","headline":"Traws Pharma Reports Second Quarter 2025 Results and Business Highlights","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":1,"phase_1":3,"phase_2":1},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}